Browse
Prediction results retrieved after performance evaluation of WHO approved 34 primers to estimate their binding affinities for 3892 SARS-CoV-2 variants.

Lineage
(WHO label)
  
Target Gene
  
Primer Name
  
Primer Sequence
  
Primer Length
  
Primer GC Content (%)
  
Start Position
  
End Position
  
Primer Direction
  
ΔG (cal)
  
Primer first used
  
AY.31 (Delta)NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
AY.51 (Delta)NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
AY.51 (Delta)NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-18259.5US
AY.122.5 (Delta)NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
AY.122.5 (Delta)NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
BA.2.40.1NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
BA.2.40.1NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
XBB.1.28NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
XBB.1.28NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
GK.3NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
GK.3NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
FL.13.5NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
FL.13.5NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
FL.10.3NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
FL.10.3NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
GS.6NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
GS.6NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
HG.2NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
HG.2NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
FD.5NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
FD.5NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
XBB.1.44NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
XBB.1.44NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
XBB.1.5.26NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
XBB.1.5.26NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
GN.3NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
GN.3NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
FW.2NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
FW.2NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
FY.1.2.2NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
FY.1.2.2NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
B.1.313NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
B.1.402NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-17121.6US
B.1.402NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
B.1.609NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
B.1.609NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
B.1.1.344NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
B.1.1.344NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
B.1.556NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
B.1.556NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
B.1.245NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
B.1.245NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
XBC.1.1NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
XBC.1.1NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
FY.9NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
FY.9NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
XBB.1.31.2NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
XBB.1.31.2NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
GK.1.2NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
GK.1.2NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
Lineage
(WHO label)
  
Target Gene
  
Primer Name
  
Primer Sequence
  
Primer Length
  
Primer GC Content (%)
  
Start Position
  
End Position
  
Primer Direction
  
ΔG (cal)
  
Primer first used